Background Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory
infection globally. There are vaccine candidates in development, but a systematic review on …

Objective The high burden associated with respiratory syncytial virus (RSV) has made the
development of RSV vaccine (s) a global health high priority. This review summarizes the …

Objective: To explore whether RSV vaccines are efficacious in preventing respiratory
syncytial virus (RSV) lower respiratory infection (LRI). Methods: Randomized clinical trials …

Respiratory syncytial virus (RSV) is a globally prevalent cause of lower respiratory infection
in neonates and infants. Despite its disease burden, a safe and effective RSV vaccine has …

Respiratory syncytial virus (RSV) poses a significant burden on public health, causing lower
respiratory tract infections in infants, young children, older adults, and immunocompromised …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

Introduction: Human respiratory syncytial virus (RSV) is a major health threat both for the
very young and the elderly. With yearly 3.2 million hospital admissions and approximately …

Respiratory syncytial virus (RSV) is the main cause of acute respiratory tract infections in
infants and it also induces significant disease in the elderly. The clinical course may be …

The development of an effective vaccine against respiratory syncytial virus (RSV) has been
hampered by major difficulties that occurred in the 1960s when a formalin-inactivated …

Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract
infection in infants and elderly and to date, there is no safe or effective vaccine against RSV …